Insilico Medicine uses generative AI to discover new drug candidates and predict their properties before expensive lab testing. The company made headlines by taking a novel AI-discovered molecule for idiopathic pulmonary fibrosis (IPF) from target identification to Phase II clinical trials in under 30 months — a process that typically takes four to six years.
Their platform, called Pharma.AI, consists of three integrated components: PandaOmics for target discovery, Chemistry42 for molecule generation, and InClinico for clinical trial outcome prediction. This end-to-end approach means Insilico can identify disease targets, design molecules to hit those targets, and predict which candidates are most likely to succeed in trials — all computationally.
Founded by Alex Zhavoronkov, a longevity researcher, Insilico initially focused on aging-related diseases before expanding to oncology, fibrosis, and other therapeutic areas. The company operates research labs in multiple countries with a strong presence in both the US and China, giving them access to diverse patient populations and regulatory pathways.
Insilico has built a pipeline of over 30 programs, with multiple candidates in clinical trials. Their IPF drug candidate, ISM001-055, represents a genuinely novel molecule that wouldn’t have been discovered through traditional screening methods. The company has raised over $400 million and established partnerships with pharmaceutical firms seeking to accelerate their own discovery timelines using Insilico’s AI infrastructure.
